Pfizer to appeal China trade mark ruling

12 February 2007

Having won an intellectual property dispute for its blockbuster erectile dysfunction agent Viagra (sildenafil) in China last year (Marketletter June 12, 2006), global drug giant Pfizer is now fighting on the trade mark front. This is on the use of the name "Wei Ge," which sounds similar to Viagra in Chinese and translates as "great man," that has been widely used in the local media and understood to be the name of the company's product. The Beijing No 1 Intermediate People's Court has ruled that Chinese drugmaker Guangzhou Wellman, which registered Wei Ge for its impotence drug, can retain the right to use it. Pfizer says that it it has filed an appeal on the ruling.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight